PRLD
Prelude Therapeutics Incorporated
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Prelude Therapeutics (PRLD) Stock: Buy, Sell, or Hold?
$3.52
-0.26 (-6.88%)
âŧ
5d:
-0.98%
30d:
+8.98%
90d:
-36.58%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (65%)
Quality Score
40/100
Position
SLIGHTLY LOW
30-Day Fair Range
$3.48 â $3.93
Position: SLIGHTLY LOW
Forward P/E & Valuation
-6.1x
CHEAP
vs 34.9x historical avg
Wall Street Target
$9.20
+161.4% upside
Options IV & Volume
11th pct IV
HIGH volume confirmation
Support / Resistance
$3.34 / $4.17
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: PRLD is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Get Alerted When PRLD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: PRLD is currently trading at $3.52, which is considered slightly low relative to its 30-day fair value range of $3.48 to $3.93. From a valuation perspective, the stock is trading at a discount (Forward PE: -6.1) compared to its historical average (34.9). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PRLD is in a downtrend. Immediate support is located at $3.34, while resistance sits at $4.17. Short-term momentum is weak, with the stock down 6.9% recently.
Market Sentiment: PRLD scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (11th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $9.20 (+161.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PRLD is in a downtrend. Immediate support is located at $3.34, while resistance sits at $4.17. Short-term momentum is weak, with the stock down 6.9% recently.
Market Sentiment: PRLD scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (11th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $9.20 (+161.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$3.48 -
$3.93
Company Quality Score
40/100
(HOLD)
Options IV Signal
11th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
65.4%
Trading Range & Key Levels
30-Day Trading Range
$3.48 -
$3.93
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
Âą$0.68
(19.5%)
Support Level
$3.34
Resistance Level
$4.17
Current Trend
Downtrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 11th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.9%)
- BULLISH: Trading 161.4% below Wall St target ($9.20)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 40/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-6.07
Wall Street Target
$9.20
(+161.4%)
Revenue Growth (YoY)
41.0%
Profit Margin
-269.8%
PE vs Historical
-6.1 vs 34.9
CHEAP
Share PRLD Analysis
Share this live PRLD analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (PRLD)
Bullish
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Jul 13, 2026
Daily AI digest
AI Retail Discussion Summary:
StockTwits messages indicate bullish sentiment towards $PRLD, with traders expecting a return to previous price levels despite recent index buying support. No relevant news articles were found.
Key Retail Themes:
price levels
market sentiment
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 13, 2026 4:48 AM ET
Data refreshes hourly during market hours. Next update: 5:48 AM
Data refreshes hourly during market hours. Next update: 5:48 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PRLD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$145 | 37 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
23 analysts |
$1147 | 31 SELL |
|
DNTH
Dianthus Therapeutics InâĻ |
STRONG BUY
18 analysts |
$139 | 41 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 39 SELL |
|
SYRE
Spyre Therapeutics Inc. |
STRONG BUY
18 analysts |
$122 | 44 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive PRLD Research Pages
